Galecto Biotech AB has raised SEK 40 million (€4.5 million) in follow-on funding from its existing investors to progress its portfolio of candidate molecules that modulate galectins, a family of proteins. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
